JP2023502108A5 - - Google Patents
Info
- Publication number
- JP2023502108A5 JP2023502108A5 JP2022528625A JP2022528625A JP2023502108A5 JP 2023502108 A5 JP2023502108 A5 JP 2023502108A5 JP 2022528625 A JP2022528625 A JP 2022528625A JP 2022528625 A JP2022528625 A JP 2022528625A JP 2023502108 A5 JP2023502108 A5 JP 2023502108A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- cdr
- cancer
- ror2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962936900P | 2019-11-18 | 2019-11-18 | |
| US62/936,900 | 2019-11-18 | ||
| PCT/US2020/061130 WO2021102055A1 (en) | 2019-11-18 | 2020-11-18 | Anti-ror-2 antibodies and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023502108A JP2023502108A (ja) | 2023-01-20 |
| JP2023502108A5 true JP2023502108A5 (cg-RX-API-DMAC7.html) | 2023-11-21 |
| JP7734661B2 JP7734661B2 (ja) | 2025-09-05 |
Family
ID=75981012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022528625A Active JP7734661B2 (ja) | 2019-11-18 | 2020-11-18 | 抗ror-2抗体および使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12643947B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4061848A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7734661B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220113951A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116018353A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020388577A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022009611A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3161617A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL293026A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022005949A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021102055A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021011494A (es) * | 2019-03-26 | 2021-12-15 | Univ California | Células t modificadas con el receptor de antígeno quimérico (t car) para el tratamiento de cánceres hematológicos y tumores sólidos. |
| CA3244077A1 (en) * | 2022-02-25 | 2023-08-31 | Bioatla, Inc. | CANCER TREATMENT WITH A CONDITIONALLY ACTIVE ANTI-ROR2 ANTIBODY-DRUG CONJUGATE |
| EP4642808A2 (en) * | 2022-12-30 | 2025-11-05 | The Regents of the University of California | Anti-ror-2 antibodies and methods of use |
| EP4739347A1 (en) | 2023-07-07 | 2026-05-13 | Solve Therapeutics, Inc. | Conjugates of drug units and targeting units and precursor compounds thereof |
| CN121181696A (zh) * | 2024-06-21 | 2025-12-23 | 深圳大学 | 一种治疗肿瘤的抗体及其应用 |
| WO2026011121A1 (en) | 2024-07-03 | 2026-01-08 | Solve Therapeutics, Inc. | Anti-ror2 antibody-drug conjugates |
| WO2026128025A2 (en) | 2024-07-03 | 2026-06-18 | Solve Therapeutics, Inc. | Anti-ror2 antibody-radionuclide conjugates |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR062709A1 (es) * | 2006-09-08 | 2008-11-26 | Genentech Inc | Antagonistas del gen wnt y su uso en el diagnostico y tratamiento de trastornos mediados por el wnt |
| GB201506407D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| CN109311982A (zh) | 2016-01-20 | 2019-02-05 | 斯克利普斯研究所 | Ror2抗体组合物和相关方法 |
| EP4122958A1 (en) | 2016-05-13 | 2023-01-25 | BioAtla, Inc. | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| CA3026151A1 (en) * | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| SG10202107808SA (en) * | 2017-01-18 | 2021-08-30 | F1 Oncology Inc | Chimeric antigen receptors against axl or ror2 and methods of use thereof |
| US11447546B2 (en) * | 2017-07-20 | 2022-09-20 | Nbe-Therapeutics Ag | Human antibodies binding to ROR2 |
-
2020
- 2020-11-18 US US17/777,591 patent/US12643947B2/en active Active
- 2020-11-18 EP EP20889747.0A patent/EP4061848A4/en active Pending
- 2020-11-18 KR KR1020227019898A patent/KR20220113951A/ko active Pending
- 2020-11-18 BR BR112022009611A patent/BR112022009611A2/pt unknown
- 2020-11-18 AU AU2020388577A patent/AU2020388577A1/en active Pending
- 2020-11-18 JP JP2022528625A patent/JP7734661B2/ja active Active
- 2020-11-18 CA CA3161617A patent/CA3161617A1/en active Pending
- 2020-11-18 MX MX2022005949A patent/MX2022005949A/es unknown
- 2020-11-18 IL IL293026A patent/IL293026A/en unknown
- 2020-11-18 WO PCT/US2020/061130 patent/WO2021102055A1/en not_active Ceased
- 2020-11-18 CN CN202080093841.5A patent/CN116018353A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2022518925A5 (cg-RX-API-DMAC7.html) | ||
| RU2018142544A (ru) | Биспецифические связывающие белки и пути их применения | |
| JP2024023228A5 (cg-RX-API-DMAC7.html) | ||
| JP2022507679A (ja) | Her2/pd1二重特異性抗体 | |
| TWI916327B (zh) | 結合pd-1的抗體 | |
| JP2020501531A5 (cg-RX-API-DMAC7.html) | ||
| JP2021512614A5 (cg-RX-API-DMAC7.html) | ||
| JP2021519072A5 (cg-RX-API-DMAC7.html) | ||
| JP2019509023A (ja) | Ror2抗体組成物及び関連する方法 | |
| CN103998468A (zh) | 抗原结合蛋白及其用作治疗癌症的定位产品的用途 | |
| WO2018119118A4 (en) | Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof | |
| TWI867218B (zh) | 靶向her2的抗原結合建構體及用途 | |
| JP2021520201A5 (cg-RX-API-DMAC7.html) | ||
| JP2024508808A5 (cg-RX-API-DMAC7.html) | ||
| JP2021512604A5 (cg-RX-API-DMAC7.html) | ||
| CA3240254A1 (en) | Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors | |
| CN105452297B (zh) | mAb 2抗-Met抗体 | |
| CA3229160A1 (en) | Bispecific tetravalent antibody targeting egfr and her3 | |
| JP7698581B2 (ja) | 抗メソテリン抗体、抗cd3抗体又は抗egfr抗体を含む融合タンパク質、それを含む二重特異性又は三重特異性抗体、及びその使用 | |
| Mazor et al. | chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5 (Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts | |
| AU2021446021A1 (en) | Anti-bcam antibody or antigen-binding fragment thereof | |
| JP2023103439A (ja) | 固形腫瘍の治療に有益な抗体およびその抗体-薬物コンジュゲート並びにこれらを含む抗がん剤 | |
| CN114539420B (zh) | 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用 | |
| JP2024517760A (ja) | 抗5t4抗体及びその使用 |